Du är här

2016-05-12

Novavax Receives the Tech Council of Maryland’s Chairman’s Award

nd’s Chairman’s Award

GAITHERSBURG, Md., 2016-05-12 14:30 CEST (GLOBE NEWSWIRE) --
Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the
discovery, development and commercialization of recombinant nanoparticle
vaccines and adjuvants, today announced it received the Tech Council of
Maryland’s (TCM) Chairman’s Award. The award was announced at the TCM Industry
Award Celebration on May 11, 2016.

The Chairman's Award is presented to a member company or individual that best
exemplifies excellence in Maryland's technology or life science industry. The
Award recognizes a company that is a pillar in the community, not only through
market success or job creation, but by consistently giving back, getting
involved and advancing the climate for innovation.

“Novavax is the embodiment of what we look for when selecting an honoree for
the Chairman’s award. The company has built a successful business, employing
450 people in Maryland who are developing vaccines that positively impact
global health, and has played an important role in fostering growth of the
state’s life sciences community,” said Rene B. LaVigne, TCM chairman-elect and
president and CEO of Iron Bow Technologies. "TCM appreciates Novavax’s
significant contributions to the association, the state’s economy and
innovations in healthcare."

“I am honored to accept this award on behalf of the entire Novavax team,” said
Stanley C. Erck, President and CEO, Novavax. “The Tech Council of Maryland
facilitates a collaborative community of technology and life science companies
who aim to make an impact in our region and beyond. We are thrilled that this
award recognizes the hard work and dedication of our more than 450 SuperNovas,
our groundbreaking achievements in developing novel vaccines and our commitment
to the Maryland life science and technology community.”

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to
delivering novel products to prevent a broad range of infectious diseases. Our
recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation
for groundbreaking innovation that improves global health through safe and
effective vaccines. Additional information about Novavax is available on the
Company's website, novavax.com.

Contact:

Novavax, Inc.
Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer

Andrea N. Flynn, Ph.D.
Associate Director, Investor Relations

ir@novavax.com
240-268-2000

Russo Partners, LLC
David Schull
Todd Davenport, Ph.D.

david.schull@russopartnersllc.com
todd.davenport@russopartnersllc.com
212-845-4271

Författare SSE

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.